This page uses content from Wikipedia and is licensed under CC BY-SA.

NNC 45-0095

NNC 45-0095
NNC 45-0095.svg
Clinical data
Other namesNNC-450095
Drug classSelective estrogen receptor modulator
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass261.324 g/mol g·mol−1
3D model (JSmol)

NC 45-0095 is a synthetic nonsteroidal selective estrogen receptor modulator (SERM) which was under development by Novo Nordisk for the treatment of postmenopausal osteoporosis but was never marketed.[1][2][3][4][5] It is a partial agonist of the estrogen receptor (IC50 (for binding inhibition) = 9.5 nM; EC50 = 13 nM) with mixed estrogenic and antiestrogenic activity, and shows full estrogenic activity in bone and uterus (Emax (relative to moxestrol, in Ishikawa endometrial cancer cell line) = 105%).[1][4] The compound is a pyrroloindolizine derivative.[1][2] Its development was discontinued by 2003.[5]

See also


  1. ^ a b c Jørgensen AS, Jacobsen P, Christiansen LB, Bury PS, Kanstrup A, Thorpe SM, Bain S, Naerum L, Wassermann K (February 2000). "Synthesis and pharmacology of a novel pyrrolo[2,1,5-cd] indolizine (NNC 45-0095), a high affinity non-steroidal agonist for the estrogen receptor". Bioorg. Med. Chem. Lett. 10 (4): 399–402. doi:10.1016/S0960-894X(00)00015-9. PMID 10714509.
  2. ^ a b Sharma, Vikas; Kumar, Vipin (2014). "Indolizine: a biologically active moiety". Medicinal Chemistry Research. 23 (8): 3593–3606. doi:10.1007/s00044-014-0940-1. ISSN 1054-2523.
  3. ^ Wallace OB, Richardson TI, Dodge JA (2003). "Estrogen receptor modulators: relationships of ligand structure, receptor affinity and functional activity". Curr Top Med Chem. 3 (14): 1663–82. doi:10.2174/1568026033451727. PMID 14683521.
  4. ^ a b Atta-ur- Rahman; Allen B. Reitz (10 December 2010). Frontiers in Medicinal Chemistry. Bentham Science Publishers. pp. 206–. ISBN 978-1-60805-205-9.
  5. ^ a b []

External links